Analysis of Gefitinib(Drug) in lung cancer.
Not Applicable
Completed
- Conditions
- Health Condition 1: null- Lung Cancer Patients
- Registration Number
- CTRI/2017/05/008490
- Lead Sponsor
- Tata Memorial Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 350
Inclusion Criteria
1)Age >= 18 years
2)Patients diagnosed with stage IV NSCLC
3)Patients planned and administered gefitinib as palliative treatment
4)ECOG Performance Status 0-3
Exclusion Criteria
1)Age < 18 years
2)Patients with lung cancers other than NSCLC
3)Patients with active cancer other than NSCLC
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall Survival in patients of NSCLC on gefitinibTimepoint: At the end of the study
- Secondary Outcome Measures
Name Time Method 1.Progression free survival in patients of NSCLC on gefitinib <br/ ><br>2.Toxicities of Gefitinib <br/ ><br>3.Quality of life of patients on Gefitinib <br/ ><br>4.Factors affecting overall survival of patients receiving gefitinib <br/ ><br>5.Response Rate <br/ ><br>Timepoint: 1. At Disease Progression <br/ ><br>2. At every Visit <br/ ><br>3. At every follow up visits <br/ ><br>4. At the End of last follow up <br/ ><br>5. Every 2-3 months